News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GTx, Inc. (GTXI) Provides Corporate Update and Second Quarter 2013 Financial Results


7/22/2013 6:39:33 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GTx, Inc. (Nasdaq: GTXI) today provides a Company update and reports financial results for the second quarter of 2013.

Clinical updates

GTx is evaluating enobosarm (GTx-024) 3 mg, an oral selective androgen receptor modulator, for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer in two pivotal Phase 3 clinical trials. The last patients completed these clinical trials during May 2013. Vital status (survival) of patients participating in the studies will continue to be periodically monitored in accordance with the clinical trial protocols.

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com

comments powered by Disqus
GTx, Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES